Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Zevra Therapeutics today and set a price target of $24.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sumant Kulkarni has given his Buy rating due to a combination of factors tied primarily to the ongoing strength and strategic importance of Miplyffa. While U.S. quarterly sales were slightly below expectations, ex-U.S. revenue via the expanded access program was notably ahead, supporting confidence that overall Miplyffa performance is robust, with further upside from guideline inclusion and potential international expansion.
Kulkarni also underscores that Zevra remains financially solid, holding a substantial cash balance with no debt, and he maintains his DCF-based price target at $24, unchanged. In addition, the Phase 3 celiprolol program for vascular Ehlers-Danlos syndrome, though not yet in his model, represents a meaningful optionality given the high unmet need and ongoing regulatory dialogue, reinforcing the positive risk-reward profile for the stock.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $26.00 price target.